The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study

Shanghai Jiao Tong University

Status: Not yet enrolling

Conditions: Diffuse Large B Cell Lymphoma (DLBCL)

Treatments: Drug: Obinutuzumab; Drug: Glofitamab

Study type: Observational

Funder types: Other

Identifiers

NCT06656234

GloReal

Details and patient eligibility

About

The purpose of this study is to evaluate the the efficacy and safety in the real-world settings of glofitamab among Chinese R/R DLBCL participants.

Enrollment: 200 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Be diagnosed as R/R DLBCL
• Participants who will be treated with glofitamab (known as being recommended and having the intention to be treated with glofitamab at the time of signing informed consent) or have initiated glofitamab treatment within 6 months prior to enrollment and after the indication approval will be observed in this study.

Exclusion criteria

• Any other reason that, in the investigator's opinion, makes the participant unsuitable to participate in this study.

Trial design

200 participants in 1 patient group

Cohort 1

Description:

Participants with relapsed or refractory (R/R) DLBCL who have started receiving glofitamab at physician's discretion in accordance with local clinical practice and/or labeling will be observed for safety and efficacy until death, withdrawal of consent, loss to follow-up or end of study whichever occurs first (up to approximately 4 years).

Treatment:

Drug: Glofitamab

Drug: Obinutuzumab